Download PDF
Semin Thromb Hemost 2022; 48(08): 926-936
DOI: 10.1055/s-0042-1749589
Review Article

Thrombotic Thrombocytopenic Purpura: From 1972 to 2022 and Beyond

James N. George
1   Department of Biostatistics and Epidemiology, Hudson College of Public Health, Hematology-Oncology Section, Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

This review tells the story of my personal experience with thrombotic thrombocytopenic purpura (TTP). It begins with my first encounter with TTP 50 years ago when 2 sisters presented 2 years apart, both pregnant and both died. At that time, I knew nothing about hereditary TTP (hTTP), the risks of pregnancy, or effective treatments. In 1991, a year after I moved to Oklahoma, therapeutic plasma exchange (TPE) was established as an effective treatment. With the availability of effective treatment, the number of patients presenting with suspected TTP soared. The diagnosis of TTP was imprecise. I worked with the Oklahoma Blood Institute (OBI) to understand the management of TTP. Because the OBI provided all TPE procedures for most of Oklahoma, we saw all consecutive patients within a defined geographic area who were identified at a uniform time early in the course of their TTP, without selection or referral bias. It was an inception cohort; this became the Oklahoma TTP Registry. In 2001, we began a very successful collaboration with the University of Bern, Switzerland, to measure ADAMTS13 activity in all of our patients. From our patients, we learned that acquired, autoimmune TTP (iTTP) is a chronic disease with risks for cognitive impairment and depression. Recognition in 2012 of three sisters with hTTP was reminiscent of the beginning of my story. hTTP has risks for multiple severe morbidities, beginning at birth and especially during pregnancy. Future management of both iTTP and hTTP will be more effective and more convenient.

Keywords

TTP - ADAMTS13 - stroke


Publication History

Article published online:
06 July 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc New York Pathol Soc 1924; 24: 21-24
    PubMedGoogle Scholar
  • 2 Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries. Arch Intern Med (Chic) 1925; 36 (01) 89-93
    CrossrefPubMedGoogle Scholar
  • 3 Singer K, Bornstein FP, Wile SA. Thrombotic thrombocytopenic purpura; hemorrhagic diathesis with generalized platelet thromboses. Blood 1947; 2 (06) 542-554
    PubMedGoogle Scholar
  • 4 Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966; 45 (02) 139-159
    CrossrefPubMedGoogle Scholar
  • 5 Fuchs WE, George JN, Dotin LN, Sears DA. Thrombotic thrombocytopenic purpura. Occurrence two years apart during late pregnancy in two sisters. JAMA 1976; 235 (19) 2126-2127
    CrossrefPubMedGoogle Scholar
  • 6 Wallace DC, Lovric A, Clubb JS, Carseldine DB. Thrombotic thrombocytopenic purpura in four siblings. Am J Med 1975; 58 (05) 724-734
    CrossrefPubMedGoogle Scholar
  • 7 Fujimura Y, Matsumoto M, Kokame K. et al. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol 2009; 144 (05) 742-754
    CrossrefPubMedGoogle Scholar
  • 8 Bukowski RM, Hewlett JS, Harris JW. et al. Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura. Semin Hematol 1976; 13 (03) 219-232
    PubMedGoogle Scholar
  • 9 Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 1977; 50 (03) 413-417
    CrossrefPubMedGoogle Scholar
  • 10 Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977; 297 (25) 1386-1389
    CrossrefPubMedGoogle Scholar
  • 11 Upshaw Jr JDJ. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978; 298 (24) 1350-1352
    CrossrefPubMedGoogle Scholar
  • 12 Rock GA, Shumak KH, Buskard NA. et al; Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325 (06) 393-397
    CrossrefPubMedGoogle Scholar
  • 13 Clark WF, Garg AX, Blake PG, Rock GA, Heidenheim AP, Sackett DL. Effect of awareness of a randomized controlled trial on use of experimental therapy. JAMA 2003; 290 (10) 1351-1355
    CrossrefPubMedGoogle Scholar
  • 14 Moake JL, Rudy CK, Troll JH. et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307 (23) 1432-1435
    CrossrefPubMedGoogle Scholar
  • 15 Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 1960; 16 (01) 943-957
    CrossrefPubMedGoogle Scholar
  • 16 Lian ECY, Harkness DR, Byrnes JJ, Wallach H, Nunez R. Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma. Blood 1979; 53 (02) 333-338
    CrossrefPubMedGoogle Scholar
  • 17 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87 (10) 4223-4234
    CrossrefPubMedGoogle Scholar
  • 18 Tsai H-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87 (10) 4235-4244
    CrossrefPubMedGoogle Scholar
  • 19 Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325 (06) 398-403
    CrossrefPubMedGoogle Scholar
  • 20 Shumak KH, Rock GA, Nair RC. Canadian Apheresis Group. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Ann Intern Med 1995; 122 (08) 569-572
    CrossrefPubMedGoogle Scholar
  • 21 Howard MA, Duvall D, Terrell DR. et al; Oklahoma TTP-HUS Study Group. A support group for patients who have recovered from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): the six-year experience of the Oklahoma TTP-HUS Study Group. J Clin Apher 2003; 18 (01) 16-20
    CrossrefPubMedGoogle Scholar
  • 22 Ambadwar P, Duvall D, Wolf NJ, Terrell DR, Vesely SK, George JN. Support groups for patients who have recovered from thrombotic thrombocytopenic purpura. J Clin Apher 2008; 23 (05) 168-169
    CrossrefPubMedGoogle Scholar
  • 23 Porta M. A Dictionary of Epidemiology. 5th ed.. Oxford, U.K.: Oxford University Press; 2008
    Google Scholar
  • 24 Furlan M, Robles R, Galbusera M. et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339 (22) 1578-1584
    CrossrefPubMedGoogle Scholar
  • 25 Tsai HM, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339 (22) 1585-1594
    CrossrefPubMedGoogle Scholar
  • 26 Gerritsen HE, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001; 98 (06) 1654-1661
    CrossrefPubMedGoogle Scholar
  • 27 Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413 (6855): 488-494
    CrossrefPubMedGoogle Scholar
  • 28 Vesely SK, George JN, Lämmle B. et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102 (01) 60-68
    CrossrefPubMedGoogle Scholar
  • 29 Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer 2013; 60 (10) 1676-1682
    CrossrefPubMedGoogle Scholar
  • 30 Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115 (08) 1500-1511 , quiz 1662
    CrossrefPubMedGoogle Scholar
  • 31 Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv 2017; 1 (10) 590-600
    CrossrefPubMedGoogle Scholar
  • 32 Ayanambakkam A, Kremer Hovinga JA, Vesely SK, George JN. Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20. Am J Hematol 2017; 92 (11) E644-E646
    CrossrefPubMedGoogle Scholar
  • 33 Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129 (01) 93-100
    CrossrefPubMedGoogle Scholar
  • 34 Froehlich-Zahnd R, George JN, Vesely SK. et al. Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica 2012; 97 (02) 297-303
    CrossrefPubMedGoogle Scholar
  • 35 Hassan A, Iqbal M, George JN. Additional autoimmune disorders in patients with acquired autoimmune thrombotic thrombocytopenic purpura. Am J Hematol 2019; 94 (06) E172-E174
    CrossrefPubMedGoogle Scholar
  • 36 Roriz M, Landais M, Desprez J. et al; French Thrombotic Microangiopathies Reference Center. Risk factors for autoimmune diseases development after thrombotic thrombocytopenic purpura. Medicine (Baltimore) 2015; 94 (42) e1598-e605
    CrossrefPubMedGoogle Scholar
  • 37 Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood 2016; 128 (17) 2175-2178
    CrossrefPubMedGoogle Scholar
  • 38 Lim W, Vesely SK, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood 2015; 125 (10) 1526-1531
    CrossrefPubMedGoogle Scholar
  • 39 Jestin M, Benhamou Y, Schelpe AS. et al; French Thrombotic Microangiopathies Reference Center. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood 2018; 132 (20) 2143-2153
    CrossrefPubMedGoogle Scholar
  • 40 Kennedy AS, Lewis QF, Scott JG. et al. Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion 2009; 49 (06) 1092-1101
    CrossrefPubMedGoogle Scholar
  • 41 Han B, Page EE, Stewart LM. et al. Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol 2015; 90 (08) 709-714
    CrossrefPubMedGoogle Scholar
  • 42 George JN. TTP: long-term outcomes following recovery. Hematology (Am Soc Hematol Educ Program) 2018; 2018 (01) 548-552
    CrossrefPubMedGoogle Scholar
  • 43 Deford CC, Reese JA, Schwartz LH. et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood 2013; 122 (12) 2023-2029 , quiz 2142
    CrossrefPubMedGoogle Scholar
  • 44 Little DJ, Reese JA, Vesely SK, George JN. Increased urinary albumin excretion following recovery from thrombotic thrombocytopenic purpura due to acquired ADAMTS13 deficiency. Am J Kidney Dis 2014; 64 (02) 317-318
    CrossrefPubMedGoogle Scholar
  • 45 Kremer Hovinga JA, George JN. Hereditary thrombotic thrombocytopenic purpura. N Engl J Med 2019; 381 (17) 1653-1662
    CrossrefPubMedGoogle Scholar
  • 46 van Dorland HA, Taleghani MM, Sakai K. et al; Hereditary TTP Registry. The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica 2019; 104 (10) 2107-2115
    CrossrefPubMedGoogle Scholar
  • 47 Tarasco E, Bütikofer L, Friedman KD. et al. Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. Blood 2021; 137 (25) 3563-3575
    CrossrefPubMedGoogle Scholar
  • 48 Borogovac A, Reese JA, Gupta S, George JN. Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura. Blood Adv 2022; 6 (03) 750-759
    CrossrefPubMedGoogle Scholar
  • 49 Kasht R, Borogovac A, George JN. Frequency and severity of pregnancy complications in women with hereditary thrombotic thrombocytopenic purpura. Am J Hematol 2020; 95 (11) E316-E318
    CrossrefPubMedGoogle Scholar
  • 50 Perez Botero J, Reese JA, George JN, McIntosh JJ. Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist. Am J Hematol 2021; 96 (12) 1655-1665
    CrossrefPubMedGoogle Scholar
  • 51 Borogovac A, Tarasco E, Kremer-Hovinga JA. et al. Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura. Blood 2022 (e-pub ahead of print).
    PubMedGoogle Scholar
  • 52 Völker LA, Kaufeld J, Miesbach W. et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv 2020; 4 (13) 3085-3092
    CrossrefPubMedGoogle Scholar
  • 53 Coppo P, Bubenheim M, Azoulay E. et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood 2021; 137 (06) 733-742
    CrossrefPubMedGoogle Scholar
  • 54 Dutt T, Shaw RJ, Stubbs M. et al. Real-world evidence of caplacizumab in the management of TTP. Blood 2021; 137 (13) 1731-1740
    CrossrefPubMedGoogle Scholar
  • 55 Chander DP, Loch MM, Cataland SR, George JN. Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019; 381 (01) 92-94
    CrossrefPubMedGoogle Scholar
  • 56 Sukumar S, George JN, Cataland SR. Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab. Am J Hematol 2020; 95 (04) E76-E77
    CrossrefPubMedGoogle Scholar
  • 57 Cuker A, Cataland SR, Coppo P. et al. Redefining outcomes in immune TTP: an international working group consensus report. Blood 2021; 137 (14) 1855-1861
    CrossrefPubMedGoogle Scholar
  • 58 Rizvi MA, Vesely SK, George JN. et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion 2000; 40 (08) 896-901
    CrossrefPubMedGoogle Scholar
  • 59 Guidry JA, George JN, Vesely SK, Kennison SM, Terrell DR. Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol 2009; 83 (03) 175-182
    CrossrefPubMedGoogle Scholar
  • 60 Upreti H, Kasmani J, Dane K. et al. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood 2019; 134 (13) 1037-1045
    CrossrefPubMedGoogle Scholar
  • 61 Shao B, Hoover C, Shi H. et al. Deletion of platelet CLEC-2 decreases GPIb alpha-mediated integrin alphaIIb-beta3 activation and decreases thrombosis in TTP. Blood 2022; 139 (16) 2523-2533
    CrossrefPubMedGoogle Scholar
  • 62 Shao B, Nusrat S, George JN, Xia L. Aspirin prophylaxis for hereditary and acquired thrombotic thrombocytopenic purpura. Am J Hematol 2022 (in press).
    PubMedGoogle Scholar
  • 63 Scully M, Knobl P, Kentouche K. et al. Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood 2017; 130 (19) 2055-2063
    CrossrefPubMedGoogle Scholar
  • 64 Peyvandi F, Scully M, Kremer Hovinga JA. et al; TITAN Investigators. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016; 374 (06) 511-522
    CrossrefPubMedGoogle Scholar
  • 65 Scully M, Cataland SR, Peyvandi F. et al; HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019; 380 (04) 335-346
    CrossrefPubMedGoogle Scholar
  • 66 Demographics of Oklahoma Wikipedia. Accessed April 2 at: 2022 https://en.wikipedia.org/
    PubMedGoogle Scholar